A. Ceccato (barcelona, Spain), K. Belchamber (Birmingham, United Kingdom)
This session is built from abstracts published on the ERS Congress platform from 23 August, in a PowerPoint format with a pre-recorded audio narration. The live session is scheduled from September 5-7 and each presenter will have a 5-minutes live, slide show presentation followed at the end of the session by 30-minutes general discussion.
Acute and sustained endothelial damage in COVID-19
R. Méndez (Valencia, Spain), P. González-Jiménez (Valencia, Spain), A. Latorre (Valencia, Spain), M. Piqueras (Valencia, Spain), L. Bouzas (Valencia, Spain), K. Yépez (Valencia, Spain), A. Ferrando (Valencia, Spain), E. Zaldívar-Olmeda (Valencia, Spain), A. Moscardó (Valencia, Spain), R. Alonso (Valencia, Spain), S. Reyes (Valencia, Spain), R. Menéndez (Valencia, Spain)
|    |
Rapid diagnosis of bacterial co-infection and antimicrobial resistance in patients with SARS-Cov-2 infection
H. Richardson (Dundee, United Kingdom), J. Maccallum (Dundee, United Kingdom), K. Falconer (Dundee, United Kingdom), D. Cassidy (Dundee, United Kingdom), M. Long (Dundee, United Kingdom), H. Keir (Dundee, United Kingdom), Y. Giam (Dundee, United Kingdom), L. Delgado (Dundee, United Kingdom), T. Pembridge (Dundee, United Kingdom), B. Parcell (Dundee, United Kingdom), S. Haynes (Dundee, United Kingdom), H. Abo-Leyah (Dundee, United Kingdom), D. Connell (Dundee, United Kingdom), J. Chalmers (Dundee, United Kingdom)
| |
Post-mortem minimally invasive tissue sampling and clinico-pathological correlation in fatal COVID-19 infection
A. Ray (New Delhi Delhi, India), N. Wig (New Delhi, India), D. Jain (New Delhi, India), P. Das (New Delhi, India), S. Arava (New Delhi, India), G. Singh (New Delhi, India), S. Agarwal (New Delhi, India), A. Goel (New Delhi, India), S. Swaroop (New Delhi, India)
| |
Tofacitinib versus standard of care treatment in patients with COVID-19 pneumonia and respiratory failure: a multicenter cohort study
L. Akulkina (Moscow, Russian Federation), M. Brovko (Moscow, Russian Federation), N. Bulanov (Moscow, Russian Federation), P. Novikov (Moscow, Russian Federation), A. Zykova (Moscow, Russian Federation), V. Sholomova (Moscow, Russian Federation), A. Moiseev (Moscow, Russian Federation), A. Schepalina (Moscow, Russian Federation), A. Kitbalian (Moscow, Russian Federation), N. Chichkova (Moscow, Russian Federation), V. Fomin (Moscow, Russian Federation), S. Avdeev (Moscow, Russian Federation), N. Trushenko (Moscow, Russian Federation), S. Moiseev (Moscow, Russian Federation)
| |
Symptom Prediction and Mortality Risk Calculation for COVID-19 Using Machine Learning
E. Jamshidi (Lausanne, Switzerland), S. Rahi (Lausanne, Switzerland), N. Mansouri (Lausanne, Switzerland)
| |
Type 1 inflammatory endotype relates to low compliance, lung fibrosis, and severe complications in COVID-19
T. Hasegawa (Hamburg, Germany), A. Nakagawa (Kobe, Japan), K. Suzuki (Kobe, Japan), K. Yamashita (Kobe, Japan), S. Yamashita (Kobe, Japan), N. Iwanaga (Kobe, Japan), E. Tamada (Kobe, Japan), K. Noda (Kobe, Japan), K. Tomii (Kobe, Japan)
| |
Comparison of COVID-19 mortality at the first and second wave adjusted for the 4C mortality score
P. Bridevaux (Sion, Switzerland), G. Gex (Sion, Switzerland), I. Frésard (Sion, Switzerland), P. Vremaroiu (Sion, Switzerland), N. Gobin (Sion, Switzerland), D. Lawi (Sion, Switzerland), R. Bouali (Sion, Switzerland)
| |
Late Breaking Abstract - Elevated NETosis and migration but impaired anti-microbial responses by COVID-19 neutrophils
K. Belchamber (Birmingham, United Kingdom), S. Thein (Birmingham, United Kingdom), J. Hazeldine (Birmingham, United Kingdom), F. Grudzinska (Birmingham, United Kingdom), M. Hughes (Birmingham, United Kingdom), A. Jasper (Birmingham, United Kingdom), K. Yip (Birmingham, United Kingdom), D. Parekh (Birmingham, United Kingdom), E. Sapey (Birmingham, United Kingdom), D. Thickett (Birmingham, United Kingdom), A. Scott (Birmingham, United Kingdom)
| |
Discussion
| |